MCKESSON CORP
MCKAPI behind this page
MCK Q1 2026 request
Playground key active
/api/financials?ticker=MCK&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 97,827 | 79,283 | +23.4% |
Show Business Segments breakouts |
|||
| International · Operating Segments | 3,738 | 3,691 | +1.3% |
| Medical-Surgical Solutions · Operating Segments | 2,701 | 2,636 | +2.5% |
| Prescription Technology Solutions · Operating Segments | 1,434 | 1,241 | +15.6% |
| U.S. Pharmaceutical · Operating Segments | 89,954 | 71,715 | +25.4% |
| Cost of Revenue | -94,548 | -76,131 | -24.2% |
| Gross Profit | 3,279 | 3,152 | +4.0% |
| Selling, General & Administrative | -2,196 | -2,001 | -9.7% |
| Restructuring Costs And Asset Impairment Charges | -47 | -10 | -370.0% |
| Operating Expenses | -2,243 | -2,123 | -5.7% |
| Operating Income | 1,036 | 1,029 | +0.7% |
| Non-Operating Income (Expense) | 64 | 130 | -50.8% |
| Interest Expense | -49 | -75 | +34.7% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | -49 | -75 | +34.7% |
| Income Loss Including Portion Attributable To Noncontrolling Interest | 1,051 | 1,084 | -3.0% |
| Income Tax Expense (Benefit) | -220 | -124 | -77.4% |
| Net Income | 831 | 960 | -13.4% |
| Net Income Loss Attributable To Noncontrolling Interest | -47 | -45 | -4.4% |
Show Equity Components breakouts |
|||
| Noncontrolling Interest | -47 | -45 | -4.4% |
Show Ownership breakouts |
|||
| ClarusONE Sourcing Services, Vantage Oncology, SCRI Oncology, and Prism Vision | -47 | -45 | -4.4% |
| Net Income | 784 | 915 | -14.3% |
| EPS (Diluted) | 6.25 | 7 | -10.7% |
| EPS (Basic) | 6.28 | 7.04 | -10.8% |
| Wtd Avg Shares (Diluted) | 125.5 | 130.7 | -4.0% |
| Wtd Avg Shares (Basic) | 124.9 | 129.8 | -3.8% |
| Income Before Taxes | 1,051 | 1,084 | -3.0% |
| Comprehensive Income | 818 | 883 | -7.4% |
| Other Comprehensive Income | 34 | -32 | +206.2% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 34 | -32 | +206.2% |
| Depreciation And Amortization | 157 | 169 | -7.1% |
Show Business Segments breakouts |
|||
| International · Operating Segments | 14 | 30 | -53.3% |
| Medical-Surgical Solutions · Operating Segments | 22 | 23 | -4.3% |
| Prescription Technology Solutions · Operating Segments | 21 | 21 | 0.0% |
| U.S. Pharmaceutical · Operating Segments | 63 | 60 | +5.0% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 37 | 35 | +5.7% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 2,418 | 2,302 | +5.0% |
| Receivables Net Current | 28,158 | 23,743 | +18.6% |
| Inventory | 25,065 | 25,571 | -2.0% |
| Prepaid Expenses & Other Current Assets | 1,160 | 636 | +82.4% |
| Total Current Assets | 56,801 | 52,252 | +8.7% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 2,574 | 2,357 | +9.2% |
| Operating Lease Right-of-Use Assets | 2,168 | 1,735 | +25.0% |
| Goodwill | 11,365 | — | — |
Show Business Segments breakouts |
|||
| International | 1,402 | — | — |
| Medical-Surgical Solutions | 2,507 | — | — |
| Prescription Technology Solutions | 2,066 | — | — |
| U.S. Pharmaceutical | 5,390 | — | — |
| Intangible Assets | 4,272 | 2,045 | +108.9% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Customer Relationships | 812 | 1,095 | -25.8% |
| Other Intangible Assets | 455 | 6 | +7483.3% |
| Service Agreements | 2,546 | 439 | +480.0% |
| Technology Based Intangible Assets | 166 | 155 | +7.1% |
| Trademarks And Trade Names | 293 | 350 | -16.3% |
| Other Non-Current Assets | 4,131 | 3,163 | +30.6% |
| Total Assets | 81,311 | 71,670 | +13.5% |
| Current Liabilities | |||
| Accounts Payable | 57,861 | 51,704 | +11.9% |
| Long Term Debt And Capital Lease Obligations Current | 1,249 | — | — |
| Operating Lease Liability Current | 297 | 296 | +0.3% |
| Accrued Liabilities | 4,924 | 4,383 | +12.3% |
| Total Current Liabilities | 64,331 | 56,434 | +14.0% |
| Non-Current Liabilities | |||
| Deferred Tax Liabilities | 987 | 928 | +6.4% |
| Operating Lease Liabilities | 1,859 | 1,466 | +26.8% |
| Litigation Reserve Noncurrent | 5,601 | 6,114 | -8.4% |
| Other Non-Current Liabilities | 2,868 | 2,525 | +13.6% |
| Long-Term Debt | 7,777 | — | — |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level2 · Fair Value Measurements Recurring | 7,777 | — | — |
Show Debt Instrument breakouts |
|||
| 0.90% Notes due December 3, 2025 · Loans Payable | 500 | — | — |
| 1.30% Notes due August 15, 2026 · Loans Payable | 499 | — | — |
| 1.50% Euro Notes due November 17, 2025 · Loans Payable | 707 | — | — |
| 1.63% Euro Notes due October 30, 2026 · Loans Payable | 589 | — | — |
| 3.13% Sterling Notes due February 17, 2029 · Loans Payable | 618 | — | — |
| 3.95% Notes due February 16, 2028 · Loans Payable | 343 | — | — |
| 4.25% Notes due September 15, 2029 · Loans Payable | 500 | — | — |
| 4.65% Notes due May 30, 2030 · Loans Payable | 650 | — | — |
| 4.75% Notes due May 30, 2029 · Loans Payable | 196 | — | — |
| 4.88% Notes due March 15, 2044 · Loans Payable | 255 | — | — |
| 4.90% Notes due July 15, 2028 · Loans Payable | 400 | — | — |
| 4.95% Notes due May 30, 2032 · Loans Payable | 650 | — | — |
| 5.10% Notes due July 15, 2033 · Loans Payable | 597 | — | — |
| 5.25% Notes due May 30, 2035 · Loans Payable | 698 | — | — |
| 6.00% Notes due March 1, 2041 · Loans Payable | 217 | — | — |
| 7.65% Debentures due March 1, 2027 · Loans Payable | 150 | — | — |
Show Long-Term Debt Type breakouts |
|||
| Lease and other obligations | 208 | — | — |
| Other Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 6,528 | 5,584 | +16.9% |
| Redeemable Noncontrolling Interest Equity Common Carrying Amount | 725 | — | — |
Show Equity Components breakouts |
|||
| Redeemable Noncontrolling Interests | 725 | — | — |
| Stockholders' Equity | |||
| Common Stock | 3 | 3 | 0.0% |
| Additional Paid-In Capital | 8,449 | 8,126 | +4.0% |
| Retained Earnings | 18,616 | 15,810 | +17.7% |
| Accumulated Other Comprehensive Income | -898 | -913 | +1.6% |
| Treasury Stock Common Value | -28,137 | -24,781 | -13.5% |
| Total Stockholders' Equity | -1,967 | -1,755 | -12.1% |
| Minority Interest | 379 | 374 | +1.3% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -1,588 | -1,381 | -15.0% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment Net Unamortized Gain Loss | 13 | -17 | +176.5% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | 10 | 3 | +233.3% |
| Accumulated Other Comprehensive Income | -898 | -913 | +1.6% |
| Accumulated Translation Adjustment | -796 | -892 | +10.8% |
| Additional Paid In Capital | 8,449 | 8,126 | +4.0% |
| Common Stock | 3 | 3 | 0.0% |
| Noncontrolling Interest | 379 | 374 | +1.3% |
| Retained Earnings | 18,616 | 15,810 | +17.7% |
| Treasury Stock Common | -28,137 | -24,781 | -13.5% |
| Unrealized Gains (Losses) on Net Investment Hedges, Net of Tax | -125 | -7 | -1685.7% |
| Total Liabilities & Equity | 81,311 | 71,670 | +13.5% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation | 62 | 63 | -1.6% |
| Adjustment For Amortization | 95 | 106 | -10.4% |
| Other Asset Impairment Charges | 2 | 3 | -33.3% |
| Increase Decrease In Deferred Income Taxes | -8 | 28 | -128.6% |
| Inventory L I F O Reserve Period Charge | -7 | -2 | -250.0% |
Show Business Segments breakouts |
|||
| U.S. Pharmaceutical · Operating Segments | -7 | -2 | -250.0% |
| Operating Lease Expense | 70 | 57 | +22.8% |
| Gain Loss On Sale Of Other Assets | 17 | -86 | +119.8% |
| Provision For Doubtful Accounts | 196 | 15 | +1206.7% |
Show Business Segments breakouts |
|||
| U.S. Pharmaceutical | 189 | — | — |
| Other Non-Cash Items | 57 | 69 | -17.4% |
| Increase Decrease In Receivables | -2,089 | -2,101 | +0.6% |
| Change in Inventory | -1,971 | -4,442 | +55.6% |
| Change in Accounts Payable | 1,947 | 4,616 | -57.8% |
| Increase Decrease In Operating Lease Liability | -89 | -96 | +7.3% |
| Increase Decrease In Accrued Taxes Payable | 134 | -211 | +163.5% |
| Increase Decrease In Other Operating Capital Net | -165 | -473 | +65.1% |
| Net Cash from Operations | -918 | -1,380 | +33.5% |
| Investing Activities | |||
| Capital Expenditures | -111 | -106 | -4.7% |
| Payments To Acquire Software | -78 | -61 | -27.9% |
| Payments To Acquire Businesses Net Of Cash Acquired | -3,359 | — | — |
| Proceeds From Divestiture Of Businesses And Interests In Affiliates | 4 | 90 | -95.6% |
| Other Investing Activities | -20 | -10 | -100.0% |
| Net Cash from Investing | -3,564 | -87 | -3996.6% |
| Financing Activities | |||
| Proceeds From Issuance Of Long Term Debt | 1,990 | — | — |
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 22 | 22 | 0.0% |
| Share Repurchases | -581 | -527 | -10.2% |
| Payments Of Dividends Common Stock | -90 | -82 | -9.8% |
| Proceeds From Payments For Other Financing Activities | -165 | -222 | +25.7% |
| Net Cash from Financing | 1,176 | -809 | +245.4% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 33 | -5 | +760.0% |
| Net Change in Cash | -3,273 | -2,281 | -43.5% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 2,683 | 2,304 | +16.4% |
| Restricted Cash Current | -265 | -2 | -13150.0% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.